

Autologous Stem Cell and Non-Stem Cell Based Therapies Market by Type
(Autologous Stem Cells, Autologous Non-Stem Cells), Application (Cancer,
Neurodegenerative Disorders, Cardiovascular Disease, Orthopedic Diseases, and
Others), End User (Hospitals, Ambulatory Surgical Centers, Research Facilities), and
Region 2023-2028

Market Report | 2023-05-29 | 144 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$2499.00
- Five User Licence \$3499.00
- Enterprisewide License \$4499.00

Report description:

Market Overview:

The global autologous stem cell and non-stem cell based therapies market size reached US\$ 6.73 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 15.39 Billion by 2028, exhibiting a growth rate (CAGR) of 13.60% during 2023-2028. The increasing prevalence of life-threatening diseases, the expanding geriatric population, and ongoing advancements in stem cell technologies represent some of the key factors driving the market.

Autologous stem cell therapy is a medical procedure in which a patient's stem cells are used to repair damaged tissues and organs or treat various diseases. The procedure involves harvesting stem cells from a patient's body, usually from bone marrow or adipose tissue, and then processing and injecting them back into the body. Non-stem cell-based therapies, on the other hand, involve using cells that are not stem cells, such as immune cells, fibroblasts, and muscle cells, to repair or regenerate damaged tissues or organs. Autologous stem cell therapy is used to treat cardiovascular diseases, neurodegenerative diseases, and autoimmune disorders, while non-stem cell-based therapies are employed in treating chronic wounds, heart disease, and Parkinson's disease.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Trends:

Scotts International. EU Vat number: PL 6772247784 tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

The growth of the global autologous stem cell and non-stem cell based therapies market is primarily driven by the increasing prevalence of cancer, diabetes, cardiovascular disorders, and neurodegenerative diseases due to smoking, poor diet, and sedentary lifestyles of consumers. Besides this, the rising geriatric population and the growing demand for autologous stem and non-stem cell based therapies are creating a positive outlook for the market. Moreover, the ongoing development of innovative autologous stem cell therapies for regenerative medicine and the widespread demand for personalized therapies are presenting remunerative growth opportunities for the market. In addition to this, the surging popularity of minimally invasive treatments, the expanding acceptance of stem cell therapies, and the implementation of favorable government initiatives, such as financial and regulatory support for stem cell research, are aiding in market expansion. Furthermore, continuous advancements in stem cell technologies have enabled researchers to better control the differentiation of stem cells and develop improved and effective treatments, which, in turn, is acting as a significant growth-inducing factor. Besides this, the bolstering growth of the healthcare sector, extensive research and development (R&D) activities, the escalating health consciousness among consumers, and favorable reimbursement policies are contributing to the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global autologous stem cell and non-stem cell based therapies market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on type, application, and end user.

Type Insights:

□Autologous Stem Cells□Autologous Non-Stem Cells

The report has provided a detailed breakup and analysis of the autologous stem cell and non-stem cell based therapies market based on the type. This includes autologous stem cells and autologous non-stem cells. According to the report, autologous stem cells represented the largest segment.

Application Insights:

□Cancer
□Neurodegenerative Disorders
□Cardiovascular Disease
□Orthopedic Diseases
□Others

A detailed breakup and analysis of the autologous stem cell and non-stem cell based therapies market based on the application has also been provided in the report. This includes cancer, neurodegenerative disorders, cardiovascular disease, orthopedic diseases, and others. According to the report, cancer accounted for the largest market share.

End User Insights:

☐Hospitals☐Ambulatory Surgical Centers

Scotts International, EU Vat number: PL 6772247784

The report has provided a detailed breakup and analysis of the autologous stem cell and non-stem cell based therapies market based on the end user. This includes hospitals, ambulatory surgical centers, and research facilities. According to the report, hospitals represented the largest segment.
Regional Insights:
□North America
□□United States
□□Canada
□Asia Pacific
□□China
□□Japan
□□India
□□South Korea
□ Australia
□□Indonesia
□□Others
□Europe
□□Germany
□□France
□□United Kingdom
□□ltaly
□□Spain
□□Russia
□□Others
□Latin America
□□Brazil
□□Mexico
□□Others
□Middle East and Africa

□Research Facilities

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for autologous stem cell and non-stem cell based therapies. Some of the factors driving the North America autologous stem cell and non-stem cell based therapies market included the expanding prevalence of chronic diseases, the rising demand for personalized medicines, and continuous advancements in stem cell technologies.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global autologous stem cell and non-stem cell based therapies market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include BrainStorm Cell Limited, Cytori Therapeutics Inc., Holostem Terapie Avanzate S.r.l., Lisata Therapeutics, U.S. Stem Cell Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global autologous stem cell and non-stem cell based therapies market performed so far, and how will it perform in the coming years?

□What are the drivers, restraints, and opportunities in the global autologous stem cell and non-stem cell based therapies market?
□What is the impact of each driver, restraint, and opportunity on the global autologous stem cell and non-stem cell based therapies market?

□What are the key regional markets?

[]Which countries represent the most attractive autologous stem cell and non-stem cell based therapies market?

 \square What is the breakup of the market based on the type?

[]Which is the most attractive type in the autologous stem cell and non-stem cell based therapies market?

 $\hfill\square\mbox{What}$ is the breakup of the market based on the application?

[]Which is the most attractive application in the autologous stem cell and non-stem cell based therapies market?

[]What is the breakup of the market based on the end user?

[]Which is the most attractive end user in the autologous stem cell and non-stem cell based therapies market?

[]What is the competitive structure of the global autologous stem cell and non-stem cell based therapies market?

[]Who are the key players/companies in the global autologous stem cell and non-stem cell based therapies market?

Table of Contents:

- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Type
- 6.1 Autologous Stem Cells
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Autologous Non-Stem Cells
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 7 Market Breakup by Application
- 7.1 Cancer
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Neurodegenerative Disorders
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Cardiovascular Disease
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Orthopedic Diseases
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Ambulatory Surgical Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Research Facilities
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast

Scotts International. EU Vat number: PL 6772247784

- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast

Scotts International. EU Vat number: PL 6772247784

- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
- 10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
- 11 Value Chain Analysis
- 12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
- 13 Price Analysis
- 14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 BrainStorm Cell Limited
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Cytori Therapeutics Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Holostem Terapie Avanzate S.r.l.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Lisata Therapeutics
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.5 U.S. Stem Cell Inc.
- 14.3.5.1 Company Overview

Scotts International. EU Vat number: PL 6772247784

14.3.5.4 SWOT AnalysisKindly note that this only represents a partial list of companies, and the complete list has been provided

14.3.5.2 Product Portfolio14.3.5.3 Financials

in the report.

Scotts International. EU Vat number: PL 6772247784 tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



To place an Order with Scotts International:

☐ - Complete the relevant blank fields and sign

Print this form

Autologous Stem Cell and Non-Stem Cell Based Therapies Market by Type (Autologous Stem Cells, Autologous Non-Stem Cells), Application (Cancer, Neurodegenerative Disorders, Cardiovascular Disease, Orthopedic Diseases, and Others), End User (Hospitals, Ambulatory Surgical Centers, Research Facilities), and Region 2023-2028

Market Report | 2023-05-29 | 144 pages | IMARC Group

RDER FORM:		
elect license	License	Price
	Electronic (PDF) Single User	\$2499.00
	Five User Licence	\$3499.00
	Enterprisewide License	\$4499.00
	VA	Г
	Tota	1
	ant license option. For any questions please contact support@scotts-international.com or 0048 603	
** VAT will be added a	rant license option. For any questions please contact support@scotts-international.com or 0048 603 at 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone*	
** VAT will be added a	at 23% for Polish based companies, individuals and EU based companies who are unable to provide	
	Phone*	

Scotts International. EU Vat number: PL 6772247784

Address*	City*	
Zip Code*	Country*	
	Date	2025-06-24
	Signature	